Literature DB >> 9135934

Model of complications of NIDDM. I. Model construction and assumptions.

R C Eastman1, J C Javitt, W H Herman, E J Dasbach, A S Zbrozek, F Dong, D Manninen, S A Garfield, C Copley-Merriman, W Maier, J F Eastman, J Kotsanos, C C Cowie, M Harris.   

Abstract

OBJECTIVE: To develop a model of NIDDM for analyzing prevention strategies for NIDDM. RESEARCH DESIGN AND METHODS: A Markov type model with Monte Carlo techniques was used. Age, sex, and ethnicity of cohort was based on U.S. data. Incidence rates of complications were also based on community and population studies.
RESULTS: Nonproliferative retinopathy, proliferative retinopathy, and macular edema are predicted in 79, 19, and 52%, respectively, of people with NIDDM; 19% are predicted to develop legal blindness. Microalbuminuria, gross proteinuria, and end-stage renal disease related to diabetes are predicted in 53, 40, and 17%, respectively. Symptomatic sensorimotor neuropathy and lower-extremity amputation are predicted in 31 and 17%, respectively. Cardiovascular disease is predicted in 39%. Higher rates of complications (1.1-3.0x) are predicted in minority populations. Predicted average life expectancy is 17 years after diagnosis.
CONCLUSIONS: A probabilistic model of NIDDM predicts the vascular complications of NIDDM in a cohort representative of the incident cases of diabetes in the U.S. before age 75 years. Predictions of complications and mortality are consistent with the known epidemiology of NIDDM. The model is suitable for evaluating the effect of preventive interventions on the natural history of NIDDM.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9135934     DOI: 10.2337/diacare.20.5.725

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  70 in total

1.  Do routine eye exams improve vision?

Authors:  Gabriel Picone; Derek Brown; Frank Sloan; Paul Lee
Journal:  Int J Health Care Finance Econ       Date:  2004-03

Review 2.  Quality improvement implementation and disparities: the case of the health disparities collaboratives.

Authors:  Marshall H Chin
Journal:  Med Care       Date:  2010-08       Impact factor: 2.983

3.  Economic Value of Improved Accuracy for Self-Monitoring of Blood Glucose Devices for Type 1 Diabetes in Canada.

Authors:  R Brett McQueen; Marc D Breton; Markus Ott; Helena Koa; Bruce Beamer; Jonathan D Campbell
Journal:  J Diabetes Sci Technol       Date:  2015-08-14

Review 4.  Model-based evaluation of diabetic foot prevention strategies in Austria.

Authors:  Marion S Rauner; Kurt Heidenberger; Eva-Maria Pesendorfer
Journal:  Health Care Manag Sci       Date:  2005-11

5.  Does comorbidity affect the benefit of intensive glycemic control in older patients with type 2 diabetes mellitus?

Authors:  Christopher D Saudek; Rita R Kalyani
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2008-12-17

6.  Requisite models for strategic commissioning: the example of type 1 diabetes.

Authors:  Mara Airoldi; Gwyn Bevan; Alec Morton; Mónica Oliveira; Jenifer Smith
Journal:  Health Care Manag Sci       Date:  2008-06

Review 7.  Screening for diabetes: what are we really doing?

Authors:  E Goyder; L Irwig
Journal:  BMJ       Date:  1998-12-12

8.  The cost-effectiveness of improving diabetes care in U.S. federally qualified community health centers.

Authors:  Elbert S Huang; Qi Zhang; Sydney E S Brown; Melinda L Drum; David O Meltzer; Marshall H Chin
Journal:  Health Serv Res       Date:  2007-12       Impact factor: 3.402

Review 9.  Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus.

Authors:  Asrul Akmal Shafie; Chin Hui Ng; Yui Ping Tan; Nathorn Chaiyakunapruk
Journal:  Pharmacoeconomics       Date:  2017-02       Impact factor: 4.981

10.  Cost effectiveness of ACE inhibitor treatment for patients with type 1 diabetes mellitus.

Authors:  Frederick B Dong; Stephen W Sorensen; Diane L Manninen; Theodore J Thompson; Venkat Narayan; Carlyn E Orians; Edward W Gregg; Richard C Eastman; Erik J Dasbach; William H Herman; Jeffrey M Newman; Andrew S Narva; David J Ballard; Michael M Engelgau
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.